Metric Finance
LearnFAQ
LearnFAQ

Learn / CSTL

NASDAQ: CSTL

Castle Biosciences (CSTL) stock, explained like you're 5

Castle Biosciences trades on the Nasdaq under the ticker CSTL. It is a small cap company in the medical specialities industry, part of the healthcare sector, with a market value of about 1.1 billion dollars.

Ticker
CSTL
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Specialities
Size
Small cap, about 1.1 billion dollars

Is Castle Biosciences a small, medium or large cap company?

No. Castle Biosciences is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.1 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Castle Biosciences makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves CSTL stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 (Yahoo Finance)
  • Castle Biosciences Q3 2026 Earnings Date and Estimates (MarketBeat)
  • Form 144 CASTLE BIOSCIENCES INC For: 18 October By Investing.com (Investing.com India)
  • The chief commercial officer proposes selling 13,154 Castle Biosciences (CSTL) shares. (Stock Titan)
  • What Castle Biosciences (CSTL)'s Barretts Test Data Means For Shareholders (Simply Wall Street)

Follow CSTL in your daily brief

Each trading day at 5 PM ET we post what happened to Castle Biosciences and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow CSTL

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Castle Biosciences stock

What does Castle Biosciences do?

Castle Biosciences trades on the Nasdaq under the ticker CSTL. It is a small cap company in the medical specialities industry, part of the healthcare sector, with a market value of about 1.1 billion dollars.

What is the ticker symbol for Castle Biosciences?

Castle Biosciences trades under the ticker CSTL on the Nasdaq.

What is Castle Biosciences's market cap?

Castle Biosciences is a small cap stock with a market cap of about 1.1 billion dollars.

How does Castle Biosciences make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves CSTL stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow CSTL stock every day?

Add CSTL to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow CSTL daily

A free brief on Castle Biosciences and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • UNH · Unitedhealth Group
  • NTRA · Natera
  • ILMN · Illumina
  • CNC · Centene

Similar stocks

  • UNHUnitedhealth Group
  • NTRANatera
  • ILMNIllumina
  • CNCCentene

Compare CSTL: CSTL vs UNH, CSTL vs NTRA, CSTL vs ILMN

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed